Last reviewed · How we verify
Primary myelofibrosis
Approved treatments
- Inrebic · Bristol-Myers Squibb
Fedratinib inhibits JAK2 and FLT3 kinases, reducing STAT3/5 phosphorylation and cell proliferation in MPNs. - Inrebic · Bristol-Myers Squibb
Inrebic works by blocking the activity of Cyclin-G-associated kinase, a protein involved in the proliferation and survival of bone marrow cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Primary myelofibrosis patent landscape — cliff calendar, originator estates, attackable patents
- Primary myelofibrosis treatment landscape brief
- Primary myelofibrosis treatment updates RSS
Frequently asked questions about Primary myelofibrosis
What drugs treat Primary myelofibrosis?
Tracked treatments include Inrebic.
What is the treatment for Primary myelofibrosis?
Standard treatment for Primary myelofibrosis includes Inrebic. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Primary myelofibrosis patent cliff · Primary myelofibrosis CI report
- Treatment: Inrebic · Bristol-Myers Squibb
- Treatment: Inrebic · Bristol-Myers Squibb
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing